Login
$ERAS
$15.11 +$0.00 (0.0%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Jonathan E. Lim, M.D. Also a director
Chairman of the Board, Chief Executive Officer, and Co-Founder
54 Not stated Not stated $4,298,838
David M. Chacko, M.D.
Chief Financial Officer and Chief Business Officer
43 Since 2023
3 years
2019 $1,778,496
Shannon R. Morris, M.D., Ph.D.
Chief Medical Officer
56 Since 2023
3 years
2022 $1,750,898
Ebun S. Garner, J.D.
Chief Legal Officer and Corporate Secretary
54 Since 2026
this year
Not stated Not reported
Charles S. Fuchs
President, Research & Development
Title from the Form 8-K dated Aug 10, 2026
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Independent
6 of 8
stated in the proxy
Average tenure
6.6 years
from year joined
CEO also chairs the board
Yes
Jonathan E. Lim
Director On board Independent Other public boards 2025 pay Source
Jonathan E. Lim
Not stated Not independent Maze Therapeutics, Inc., Boundless Bio, Inc. Paid as CEO
Alexander W. Casdin
2018
8 years
Independent None stated $176,908
Julie Hambleton
2021
5 years
Independent None stated $175,408
Michael D. Varney
2020
6 years
Not independent None stated Not stated
Jean I. Liu
2022
4 years
Independent Connect Biopharma Holdings Limited $169,408
Pratik S. Multani
2018
8 years
Independent None stated $166,908
James A. Bristol
2018
8 years
Independent Ernexa Therapeutics, Inc. Not stated
Valerie Harding-Start
2019
7 years
Independent None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 28, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support